Pathological Gambling: Diagnosis and Epidemiology

Pathological gambling, characterized by the inability to resist the urge to gamble despite severe consequences, is a progressively worsening disorder. This text discusses the diagnostic criteria for pathological gambling, its positive diagnosis according to DSM-IV-TR, and epidemiological data on the prevalence of problem gambling in Romania, focusing on adolescents.

• Pathological Gambling
• Diagnosis
• Epidemiology
• DSM-IV-TR
• Romania

asly956 Follow

Uploaded on Nov 12, 2024 | 0 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

Presentation Transcript

2. Cocea Eduard-Natanael medic rezident an II

3. Date generale Jocul de noroc patologicestecea mai frecventa tulburarede control al impulsurilor,caracterizata prin esecul recurentde a rezista impulsului de a juca,in ciudaconsecintelor negative severe si devastatoare in plan personal,profesional,familial. Este o tulburare progresivacaracterizata prin pierderea continua sau periodica a controlului asupra jocului de noroc,preocuparea pentru jocuri de norocsi pentru obtinerea banilor,in scopul de a juca,gandirea irationala si continuareacomportamentului in ciuda consecintelor negative.

4. Diagnostic pozitiv Criteriile DSM IV TR Joc de noroc maladaptativ persistent si recurent indicat de cinci(sau mai multe) din urmatoarele: 1)Este preocupatde jocurilede noroc(de ex: preocupatde retrairea experientelortrecutede joc,schemede handicapuri sau planuirea urmatoarei sesiuni ,sau se gandeste la modurilede a obtine bani pentru a juca); 2)Trebuiesa joace sumede bani din ce in ce mai mari pentru a realiza excitatia dorita; 3)A facut in mod repetateforturi lipsite de succesde a controla,reducesau incetasa mai joace; 4)Este nelinistit sau iritabil atunci cand incearcasa reduca sau sa incetezesa mai joace; 5)Jocul este un mod de a se inteparta de problemesau de a inlatura o dispozitie disforica(de ex: simtaminte de neajutorare,vinovatie,anxietate,depresie); 6)Dupace pierde bani la joc,adeseori se intoarcea doua zi ca sa isi ea revansa(isi haituieste pierderile); 7)Ii minte pe membrii de familie,terapeut,pealtii,pentru a ascundegradul de implicare in jocurile de noroc; 8)A comis acte ilegale,cum ar fi falsuri,fraude,furtsau delapidare pentru a avea bani de joc; 9)A periclitat sau a pierduto relatie semnificativa,slujba sau o oportunitateeducationala sau din cariera din cauza jocurilorde noroc; 10)Se bazeaza pealtii ca sa-i dea banii cu care sa iasa dintr-o situatie financiara disperata cauzata de joc;

5. epidemiologie Datele legate de prevalenta jucatorilor patologici in randul populatiei din Romania nu sunt foarte numeroase 1032 de adolescenti ; varstecuprinse intre 11-19 ani:65.7% sex masculin 34,43% sex feminin Subiectii au fost impartiti in 3 grupuri: nejucatori/jucatori ocazionali:753 subiecti(72,96% din total):316 sex feminin si 437 sex masculin jucatori de noroc problematici:243 de subiecti=23,54 43 de sex feminin si 200 de sex masculin 3.jucatori de noroc patologici=36 de subiecti -3,48% din totalul subiectilor dintrecare 3 de sex feminin si 33 sex masculin 1. 2.

6. Jucatorii de noroc patologici Numarsubiecti:36 Varsta medie= 16,48 ani. Diferenta pe sexea fostsemnificativa -subiectii de sex masculin: 91,66% -sex feminin 8,33%. Jocuri practicate:pariurile sportive si "pacanelele -36,11% lotosi casino online au urmatcu 25% ruletasi black-jackul cu 22,22%. Din acestia 66,66% consumau alcool, 33,32% droguri legale sau ilegale .Doar 16% consumau tutun.

7. Scopul acestei prezentari este de a realiza o sinteza a multiple studii dublu orb, controlate placebo a diversilor agenti farmaceutici utilizati si a efectelor acestora.Am folosit studii efectuate in perioada 2004-2014.Studiile pe care le-am luat in considerare pentru aceasta prezentare includ antidepresive, antagonisti opiozi, timostabilizatoare,antipsihotice atipice, si agenti glutamatergici . In ciuda impactului personal i social al dependen ei de jocuri de noroc, nu exista inca un consens in privinta unei medicatii clare in jocul de noroc patologic.Am analizat 18 studii ale agentilor farmacologici enumerati anterior si multe dintre aceste studii sugereaza ca anumite terapii medicamentoase pot fi benefice in tratarea tulburarii.

8. Antidepresivele au fost una dintre primele clase de medicamente folosite pentru a trata jocul de noroc patologic, avand la baz asocierea jocului de noroc patologic si a compulsivitatii, date care arata o disfunctie serotoninergica in jocul de noroc patologic,posibilitatea de a folosi clomipramina de a trata jocul de noroc patologic si folosirea fluvoxaminei pentru a trata cumparatul compulsiv, o tulburarece face parte din spectrul tulburarilor obsesiv-compulsive. Cercet rile ulterioare s-au axat pe similitudinile dintre simptomele clinice ale jocului de noroc patologic si utilizarea de substante psiho-active, precum: -lipsa de control -cresterea tolerantei -continuarea implicarii intr-un anumit comportament in ciuda consecintelor negative si caile neurologice similare pentru jocul de noroc patologic si adictia de substante psiho-active care a dus la explorarea antagonistilor opiozi ca optiune de tratament. Mai multe studii recente au eviden iat existen a unor subtipuri de joc de noroc patologic i alte aspecte relevante pentru aceasta tulburare cum ar fi comorbiditatile si antecedentele psihiatrice ale membrilor familiei ce a dus la examinarea stabilizatorilor de dispozi ie, antipsihoticelor atipice, agen ilor glutamatergici si antipsihoticelor atipice ca terapii farmacologice eficiente.

9. antidepresive Paroxetina:doza initiala 20 mg/zi, crescuta cu 10 mg/saptamana pana la 60 mg/zi S1:-8 s pt m ni -45 subiecti - 61% dintre subiec i au prezentato ameliorare la paroxetina fata de doar 23% la placebo. S2:-16 saptamani -76 subiecti - 59% dintre subiec i au prezentato ameliorare la paroxetinasi 48% la placebo(diferenta nu este una semnificativa in favoarea proxetinei) -rata ridicata de raspuns la placebo

10. antidepresive Fluvoxamina S1:-207 mg/zi -16 saptamani -15 subiecti -rezultate:eficientasemnificativa in tratarea tulburarii S2:-200 mg/zi -6 luni -32 subiecti -rezultate nesemnificative;

11. antidepresive S:-sertralina 95 mg/zi -6 luni -60 subiecti -rezultate o dpdv statistic S:-bupropiona -12 saptamani -39 subiecti -rezultate o dpdv statistic

12. Antagonisti opiozi Avand in vedere capacitatea lor de a modula transmisia dopaminergica in calea mezolimbica, antagonistii receptorilor opiozi au fost investigati in tratamentul jocului de noroc patologic. Naltrexonaeste un medicament folosit in principal pentru tratamentul dependentei de alcool, in reducerea intensitatii nevoii de a juca, gandurile si comportamentul legat de jocurilede noroc.

13. Naltrexona S1:-11 saptamani -45 subiecti -rata de raspuns 75% fatade 24% in grupul placebo -cei cu o intensitate mai mare a dorintei de a juca au raspuns mai eficient la tratament S2:-18 saptamani -77 subiecti - reduceri semnificativ mai mari in dorinta de a juca jocuri de noroc si comportamente legate de jocurile de noroc comparativ cu subiectii din grupul placebo - La sfarsitul studiului 39,7 % din cei cu naltrexona au putut s se ab in de la toate jocurile de noroc pentru cel pu in 1 luna fatade numai 10,5 % din cei cu placebo

14. Antagonisti opiozi Nalmefena S1:-16 saptamani -207 pacienti -59% au aratat reduceri semnificative ale dorintei, gandurilor si comportamentelor legate de jocurile de noroc comparativ cu 34% in randul celorcu placebo S2:-dozavariabila:20 si 40 mg -16 saptamani -233 subiecti -rezultatesuperioare in randul celorcare primeau 40 mg/zi fatade cei cu 20mg/zi sau placebo - dozajul agentului farmacologic poate fi important in controlul simptomelor.

15. Antagonisti opiozi Avand in vedere ca doua studii dublu orb controlate placebo ale naltrexonei si 2 studii ale nalmefenei sugereaza eficacitatea antagonistilor opiozi in reducereadorintei de a juca, gandurilorsi comportamentelor asociate jocurilor de noroc, aceasta clasa de medicamente ar trebui considerata prima linie de tratament in jocul de noroc patologic. Un studiu de follow-up realizat la 6 luni dupa, a constatat ca majoritatea celor care au raspuns la naltrexona au mentinut raspunsul si dupa intreruperea mediatiei.

16. Timostabilizatoarele S:-Carbonatde litiu cu eliberare prelungita -10 saptamani -40 de subiecti(tulburari din spectrul bipolar si joc de noroc patologic) -rezultate imbunatatiresemnificativa: 83% pt Carb. de litiu fatade 29 % din grupul placebo S:-Topiramat -14 saptamani -42 subiecti -rezultate -nesemnificative

17. Antipsihotice atipice Olanzapina:5-10 mg/zi S1:-12 saptamani -42 subiecti -rezultate o dpdv statistic S2:-7 saptamani -21 subiecti -rezultate 0 dpdv statistic

18. limitari numar redus de subiecti durata limitata grupuri clinice nereprezentative

19. Concluzii Cercet rile privind tratamentul farmacologic al jocului de noroc patologic par promi toare, n special n cazul antagoni tilor opioizi.Totusi cercetatorii si clinicienii ar trebui sa fie constienti de limitarile cunostintelor noastre in aceasta privinta. Cercetarea ulterioara ar trebui sa asigure un numar mai mare de subiecti cu joc de noroc patologic, pe perioade mai mari de timp si care sunt evaluate longitudinal pe o perioada de cativa ani .

20. 1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.Washington DC: American Psychiatric Association; 2000. 2. Hodgins DC, Stea JN, Grant JE. Gambling disorders. Lancet. 2011;378:1874 1884. 3. Gerstein D, Murphy S, Toce M, Hoffman J, Palmer A, Johnson R, Larison C, Chuchro L, Buie T, Engelman L, Hill MA, Volberg R, Harwood H, Tucker A, Christiansen E, Cummings W, Sinclair S. Gambling Impact and Behavior Study: Final Report to the National Gambling Impact Study Commission. Chicago, IL: National Opinion Research Center (NORC); 1999. 4. Grant JE, Kim SW. Demographic and clinical characteristics of 131 adult pathological gamblers. J Clin Psychiatry. 2001;62:957 962. 5. Morasco BJ, Petry NM. Gambling problems and health functioning in individuals receiving disability. Disabil Rehabil. 2006;28:619 623. 6. Hong SI, Sacco P, Cunningham-Williams RM. An empirical typology of lifetime and current gambling behaviors: association with health status of older adults. Aging Ment Health. 2009;13:265 273. 7. Chou KL, Afifi TO. Disordered (pathologic or problem) gambling and axis I psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Am J Epidemiol. 2011;173:1289 1297. 8. Grant JE, Kim SW. Quality of life in kleptomania and pathological gambling. Compr Psychiatry. 2005;46:34 37. 9. Black DW, Moyer T, Schlosser S. Quality of life and family history in pathological gambling. J Nerv Ment Dis. 2003;191:124 126. 10. Ledgerwood DM, Petry NM. Gambling and suicidality in treatment-seeking pathological gamblers. J Nerv Ment Dis. 2004;192:711 714. 11. Van den Brink W. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr Drug Abuse Rev. 2012;5:3 31. 12. Achab S, Khazaal Y. Psychopharmacological treatment in pathological gambling: a critical review. Curr Pharm Des. 2011;17:1389 1395. 13. Hollander E, editor. Obsessive-Compulsive Related Disorders. Washington DC: American Psychiatric Press, Inc; 1993. 14. Moreno I, Saiz-Ruiz J, Lopez-Ibor JJ. Serotonin and gambling dependence. Hum Psychopharmacol. 1991;6:S9 12. 15. Carrasco JL, Saiz Ruiz J, Moreno I, Hollander E, Lopez-Ibor JJ. Low platelet MAO activity in pathological gambling. Acta Psychiatr Scand. 1994;90:427 431. 16. Decaria CM, Hollander EH, Grossman R, Wong CM, Mosovich SA, Cherkasky S. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry.1996;57:80 84. 17. Hollander D, Frenkel M, Decaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine.Am J Psychiatry. 1992;149:710 711. 18. Black DW, Mohnahn P, Gabel J. Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry. 1997;58:159 163. 19. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914 921. 20. Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry. 1998;59:159 164. 21. Dannon PN, Lowngrub K, Gonopolski Y, Musin E, Kolter M. Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder. Primary Care Companion. J Clin Psychiatry. 2006;8:334 339. 22. Blanco C, Moreyra P, Nunes EV, S iz-Ruiz J, Ib ez A. Pathological gambling: addiction or compulsion? Semin Clin Neuropsychiatry. 2001;6:167 176. 23. Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a criticial review. Clin Pract Epidemol Ment Health. 2005;1:21. 24. Shah KR, Eisen SA, Xian H, Potenza MN. Genetic studies of pathological gambling: a review of methodology and analysis of data from the Vietnam Era Twin Registry. J Gambl Stud. 2005;21:179 203. 25. Black DW, Monahan PO, Temkit M, Shaw M. A family study of pathological gambling.Psychiatry Res. 2006;141:295 303.

21. 25. Black DW, Monahan PO, Temkit M, Shaw M. A family study of pathological gambling.Psychiatry Res. 2006;141:295 303. [ 26. Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501 507. 27. Grant JE, Kim SW, Potenza MN, Blanco C, Ib ez A, Stevens L, Hektner JM, Zaninelli R. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial.Int Clin Psychopharmacol. 2003;18:243 249. 28. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry.2000;47:813 817. 29. Blanco C, Petkova E, Ib ez A, S iz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9 15. 30. Chung SK, You IH, Cho GH, Chung GH, Shin YC, Kim DJ, Choi SW. Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009;50:441 444. 31. S iz-Ruiz J, Blanco C, Ib ez A, Masramon X, G mez MM, Madrigal M, D ez T. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66:28 33. 32. Black DW, Arndt S, Coryell WH, Argo T, Forbush KT, Shaw MC, Perry P, Allen J. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007;27:143 150. 33. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of pathological gambling urges. J Clin Psychiatry.2008;69:783 789. 34. Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18:219 225. 35. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303 312. 36. Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo- controlled study. Br J Psychiatry.2010;197:330 331. 37. Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol. 2007;27:620 624. 38. Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl)2008;200:521 527. 39. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137 145. 40. Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, LiCalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological gamblers. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism.Neuropsychobiology. 2008;58:37 47. 41. Dannon PN, Lowengrub K, GonopolskiY, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randmized, blind-rater comparison study. Clin Neuropharmacol. 2005;28:6 10. 42. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry. 2011 Epub April 12;doi: 10.3109/15622975.2011.560964. 43. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE., Jr Olanzapine in the treatment of pathological gambling: a negative randomized placebo- controlled trial. J Clin Psychiatry.2008;69:e1 8. 44. Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers.Pharmacol Biochem Behav. 2008;89:298 303.

22. 45. Kalivas PW, Peters J, Knackstedt L. Animal models and brain circuits in drug addiction.Mol Interv. 2006;6:339 344. 46. Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict. 2010;19:187 189. 47. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. EurAddict Res. 2011;17:211 216. 48. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62:652 657. 49. Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology. 2004;29:195 207. 50. Chamberlain SR, Grant JE, Costa A, M ller U, Sahakian BJ. Effects of acute modafinil on cognition in trichotillomania. Psychopharmacology (Berl) 2010;212:597 601. 51. Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl) 2010;212:603 612.

23. Va multumesc!